Tom Newsom-Davis
@tnewsomdavis.bsky.social
Thoracic medical oncologist | Chelsea & Westminster Hospital, London, UK | Chair British Thoracic Oncology Group
Not only does ‘Repositories of Agriculture’ debase scientific publications through unsolicited paper requests, but they then get aggressive when you don’t reply.
Extraordinary
Think they need to review their PR skills (and conscience)
Extraordinary
Think they need to review their PR skills (and conscience)
April 22, 2025 at 12:00 PM
Not only does ‘Repositories of Agriculture’ debase scientific publications through unsolicited paper requests, but they then get aggressive when you don’t reply.
Extraordinary
Think they need to review their PR skills (and conscience)
Extraordinary
Think they need to review their PR skills (and conscience)
❗️BTOG / NLCA ‘State of the Nation’ webinar on 15th May❗️
The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK
Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍
The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK
Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍
April 9, 2025 at 12:32 PM
❗️BTOG / NLCA ‘State of the Nation’ webinar on 15th May❗️
The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK
Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍
The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK
Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍
UK Oncologist’s Garden:
The pear trees are just in blossom
The pear trees are just in blossom
March 31, 2025 at 1:31 PM
UK Oncologist’s Garden:
The pear trees are just in blossom
The pear trees are just in blossom
‘No evidence that patient survival is improved with surgery’
Curious wording from NCCN, given that MARS2 found that epithelioid histology pts had 12% higher risk of death if they had surgery…
Curious wording from NCCN, given that MARS2 found that epithelioid histology pts had 12% higher risk of death if they had surgery…
March 28, 2025 at 8:49 PM
‘No evidence that patient survival is improved with surgery’
Curious wording from NCCN, given that MARS2 found that epithelioid histology pts had 12% higher risk of death if they had surgery…
Curious wording from NCCN, given that MARS2 found that epithelioid histology pts had 12% higher risk of death if they had surgery…
Predicting surgical complexity following neo-adjuvant chemoIO
Single centre 🇬🇧 study
👉 43% defined as complex
🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%
#ELCC25
Single centre 🇬🇧 study
👉 43% defined as complex
🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%
#ELCC25
March 28, 2025 at 2:37 PM
Predicting surgical complexity following neo-adjuvant chemoIO
Single centre 🇬🇧 study
👉 43% defined as complex
🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%
#ELCC25
Single centre 🇬🇧 study
👉 43% defined as complex
🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%
#ELCC25
LAURA OS update (LBA4)
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
March 28, 2025 at 2:10 PM
LAURA OS update (LBA4)
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
Great ROS1 TKI summary slide from Julian Mazieres
March 27, 2025 at 4:07 PM
Great ROS1 TKI summary slide from Julian Mazieres
COCOON: mitigating cutaneous toxicity of Amivantamab
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
March 27, 2025 at 4:05 PM
COCOON: mitigating cutaneous toxicity of Amivantamab
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
Case controlled indirect comparison of Taletrectinib v Crizotinib in ROS1 NSCLC
👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs
💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data
#ELCC25
👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs
💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data
#ELCC25
March 27, 2025 at 3:55 PM
Case controlled indirect comparison of Taletrectinib v Crizotinib in ROS1 NSCLC
👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs
💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data
#ELCC25
👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs
💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data
#ELCC25
Tobemstomig (LAG3/PD1 bispecific) + chemo in 1L NSCLC
👉 Randomised Ph2
❌ No ORR benefit
❌ No PFS benefit
❌ Higher Gr3+ TRAEs
💭 Not active combination
💭 Reality check on growing bispecific excitement
💭 Disappointing. LAG3 is hard to target.
#ELCC25
👉 Randomised Ph2
❌ No ORR benefit
❌ No PFS benefit
❌ Higher Gr3+ TRAEs
💭 Not active combination
💭 Reality check on growing bispecific excitement
💭 Disappointing. LAG3 is hard to target.
#ELCC25
March 27, 2025 at 3:47 PM
Tobemstomig (LAG3/PD1 bispecific) + chemo in 1L NSCLC
👉 Randomised Ph2
❌ No ORR benefit
❌ No PFS benefit
❌ Higher Gr3+ TRAEs
💭 Not active combination
💭 Reality check on growing bispecific excitement
💭 Disappointing. LAG3 is hard to target.
#ELCC25
👉 Randomised Ph2
❌ No ORR benefit
❌ No PFS benefit
❌ Higher Gr3+ TRAEs
💭 Not active combination
💭 Reality check on growing bispecific excitement
💭 Disappointing. LAG3 is hard to target.
#ELCC25
Pan-KRASi: RMC-6236
👉 NSCLC pts from Ph1 study
❇️ 200mg = Ph3 dose
❗️TRAE: mucocutaneous, GI, liver
❗️ Rash prophylaxis needed
👉 Clinical data from G12X popn:
❇️ ORR 38%
❇️ mPFS = 9.8m
Ph3 RASolve-301 underway
💭 Need breakdown by mutant type
💭 Press release: safe combo w Pembro
#ELCC25
👉 NSCLC pts from Ph1 study
❇️ 200mg = Ph3 dose
❗️TRAE: mucocutaneous, GI, liver
❗️ Rash prophylaxis needed
👉 Clinical data from G12X popn:
❇️ ORR 38%
❇️ mPFS = 9.8m
Ph3 RASolve-301 underway
💭 Need breakdown by mutant type
💭 Press release: safe combo w Pembro
#ELCC25
March 27, 2025 at 3:28 PM
Pan-KRASi: RMC-6236
👉 NSCLC pts from Ph1 study
❇️ 200mg = Ph3 dose
❗️TRAE: mucocutaneous, GI, liver
❗️ Rash prophylaxis needed
👉 Clinical data from G12X popn:
❇️ ORR 38%
❇️ mPFS = 9.8m
Ph3 RASolve-301 underway
💭 Need breakdown by mutant type
💭 Press release: safe combo w Pembro
#ELCC25
👉 NSCLC pts from Ph1 study
❇️ 200mg = Ph3 dose
❗️TRAE: mucocutaneous, GI, liver
❗️ Rash prophylaxis needed
👉 Clinical data from G12X popn:
❇️ ORR 38%
❇️ mPFS = 9.8m
Ph3 RASolve-301 underway
💭 Need breakdown by mutant type
💭 Press release: safe combo w Pembro
#ELCC25
ORCHARD (module 10): Osi + Dato-Dxd post 1L Osi
❇️ ORR 36 - 43%
❇️ mPFS 9.5 - 11.7m
❇️ DoR longer in 6mg/kg grp
❗️ 65% Dato dose reduction
❗️ 60% Dato dose interr
💭 Active combination
💭 Toxic+
💭 Not biomarker directed
#ELCC25
❇️ ORR 36 - 43%
❇️ mPFS 9.5 - 11.7m
❇️ DoR longer in 6mg/kg grp
❗️ 65% Dato dose reduction
❗️ 60% Dato dose interr
💭 Active combination
💭 Toxic+
💭 Not biomarker directed
#ELCC25
March 26, 2025 at 4:54 PM
ORCHARD (module 10): Osi + Dato-Dxd post 1L Osi
❇️ ORR 36 - 43%
❇️ mPFS 9.5 - 11.7m
❇️ DoR longer in 6mg/kg grp
❗️ 65% Dato dose reduction
❗️ 60% Dato dose interr
💭 Active combination
💭 Toxic+
💭 Not biomarker directed
#ELCC25
❇️ ORR 36 - 43%
❇️ mPFS 9.5 - 11.7m
❇️ DoR longer in 6mg/kg grp
❗️ 65% Dato dose reduction
❗️ 60% Dato dose interr
💭 Active combination
💭 Toxic+
💭 Not biomarker directed
#ELCC25
SAVANNAH: Osi+Savolitinib in MET amp/OE EGFR+ post 1L Osi
👉 Protocol evolved over time
👉 34% pts have MET OE/amp
❇️ ORR 56%; mDOR 9.9m
❇️ mPFS 7.5m
❗️32% Gr3+ AE: oedema, N&V, diarr
❗️Dose amendments mainly for Savo
💭 Good that includes MET OE
💭 Expected side effects, not insignificant
👉 Protocol evolved over time
👉 34% pts have MET OE/amp
❇️ ORR 56%; mDOR 9.9m
❇️ mPFS 7.5m
❗️32% Gr3+ AE: oedema, N&V, diarr
❗️Dose amendments mainly for Savo
💭 Good that includes MET OE
💭 Expected side effects, not insignificant
March 26, 2025 at 4:30 PM
SAVANNAH: Osi+Savolitinib in MET amp/OE EGFR+ post 1L Osi
👉 Protocol evolved over time
👉 34% pts have MET OE/amp
❇️ ORR 56%; mDOR 9.9m
❇️ mPFS 7.5m
❗️32% Gr3+ AE: oedema, N&V, diarr
❗️Dose amendments mainly for Savo
💭 Good that includes MET OE
💭 Expected side effects, not insignificant
👉 Protocol evolved over time
👉 34% pts have MET OE/amp
❇️ ORR 56%; mDOR 9.9m
❇️ mPFS 7.5m
❗️32% Gr3+ AE: oedema, N&V, diarr
❗️Dose amendments mainly for Savo
💭 Good that includes MET OE
💭 Expected side effects, not insignificant
MARIPOSA final OS analysis
❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease
❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important
More effective than Osimertinib
Most suitable for higher risk pts
#ELCC25
❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease
❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important
More effective than Osimertinib
Most suitable for higher risk pts
#ELCC25
March 26, 2025 at 4:07 PM
MARIPOSA final OS analysis
❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease
❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important
More effective than Osimertinib
Most suitable for higher risk pts
#ELCC25
❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease
❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important
More effective than Osimertinib
Most suitable for higher risk pts
#ELCC25
March 26, 2025 at 3:17 PM
March 26, 2025 at 12:26 PM
Are you a respiratory or oncology trainee interested in lung cancer?
Then apply to be part of the amazing @btog.bsky.social steering committee
⭐ Great experience
⭐ Great for your CV
⭐️ Great fun
⭐️ Great people
⭐ Great cause
❗️ Deadline 30.04.25
Then apply to be part of the amazing @btog.bsky.social steering committee
⭐ Great experience
⭐ Great for your CV
⭐️ Great fun
⭐️ Great people
⭐ Great cause
❗️ Deadline 30.04.25
March 26, 2025 at 10:25 AM
Are you a respiratory or oncology trainee interested in lung cancer?
Then apply to be part of the amazing @btog.bsky.social steering committee
⭐ Great experience
⭐ Great for your CV
⭐️ Great fun
⭐️ Great people
⭐ Great cause
❗️ Deadline 30.04.25
Then apply to be part of the amazing @btog.bsky.social steering committee
⭐ Great experience
⭐ Great for your CV
⭐️ Great fun
⭐️ Great people
⭐ Great cause
❗️ Deadline 30.04.25
New chemotherapy unit & treatment centre at West Middlesex Hospital coming on nicely
Chemo unit on top floor 😊
ETA 2026
Chemo unit on top floor 😊
ETA 2026
March 6, 2025 at 5:39 PM
New chemotherapy unit & treatment centre at West Middlesex Hospital coming on nicely
Chemo unit on top floor 😊
ETA 2026
Chemo unit on top floor 😊
ETA 2026
@stephenvliu.bsky.social: SCLC, ADCs
❇️ TROP2: has potential, respectable 40% ORR
❇️ SEZ6: impressive depth of response, but early days
❇️ B7-H3: most impressive efficacy, but ❗️toxicity - especially ILD
But exciting developments:
There is a New Hope in SCLC
❇️ TROP2: has potential, respectable 40% ORR
❇️ SEZ6: impressive depth of response, but early days
❇️ B7-H3: most impressive efficacy, but ❗️toxicity - especially ILD
But exciting developments:
There is a New Hope in SCLC
March 5, 2025 at 12:18 PM
@stephenvliu.bsky.social: SCLC, ADCs
❇️ TROP2: has potential, respectable 40% ORR
❇️ SEZ6: impressive depth of response, but early days
❇️ B7-H3: most impressive efficacy, but ❗️toxicity - especially ILD
But exciting developments:
There is a New Hope in SCLC
❇️ TROP2: has potential, respectable 40% ORR
❇️ SEZ6: impressive depth of response, but early days
❇️ B7-H3: most impressive efficacy, but ❗️toxicity - especially ILD
But exciting developments:
There is a New Hope in SCLC
Congratulations to our Research Fellow, Iakov, for his prize winning poster on neo-adjuvant NSCLC who do not proceed to surgery
Iakov is a rising star, and has a bright future ahead of him
Iakov is a rising star, and has a bright future ahead of him
March 5, 2025 at 10:42 AM
Congratulations to our Research Fellow, Iakov, for his prize winning poster on neo-adjuvant NSCLC who do not proceed to surgery
Iakov is a rising star, and has a bright future ahead of him
Iakov is a rising star, and has a bright future ahead of him
Graham Warren on smoking cessation in lung cancer pts.
Extraordinary data:
🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit
Sensational talk 🤯
Extraordinary data:
🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit
Sensational talk 🤯
March 5, 2025 at 9:23 AM
Graham Warren on smoking cessation in lung cancer pts.
Extraordinary data:
🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit
Sensational talk 🤯
Extraordinary data:
🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit
Sensational talk 🤯
Great oral presentation of NLCA NSCLC SACT data from Lauren Dixon
❗️Only 62% PS0/1 got SACT
❗️Big variation between Alliances
❗️Variation also according to age, frailty & SE status
❗️Only 62% PS0/1 got SACT
❗️Big variation between Alliances
❗️Variation also according to age, frailty & SE status
March 4, 2025 at 5:56 PM
Great oral presentation of NLCA NSCLC SACT data from Lauren Dixon
❗️Only 62% PS0/1 got SACT
❗️Big variation between Alliances
❗️Variation also according to age, frailty & SE status
❗️Only 62% PS0/1 got SACT
❗️Big variation between Alliances
❗️Variation also according to age, frailty & SE status
Brilliant, and witty, talk by Houda Bahig
❇️ When looking at perioperative chemoIO, control arm assumes surgery is best approach. Which it may not be…
❇️ Need to consider what happens when chemoIO fails: salvage therapies rarely possible
❇️ When looking at perioperative chemoIO, control arm assumes surgery is best approach. Which it may not be…
❇️ Need to consider what happens when chemoIO fails: salvage therapies rarely possible
March 4, 2025 at 12:37 PM
Brilliant, and witty, talk by Houda Bahig
❇️ When looking at perioperative chemoIO, control arm assumes surgery is best approach. Which it may not be…
❇️ Need to consider what happens when chemoIO fails: salvage therapies rarely possible
❇️ When looking at perioperative chemoIO, control arm assumes surgery is best approach. Which it may not be…
❇️ Need to consider what happens when chemoIO fails: salvage therapies rarely possible